Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II

被引:0
作者
Koster, A
Hansen, R
Grauhan, O
Hausmann, H
Bauer, M
Hetzer, R
Kuppe, H
Mertzlufft, F
机构
[1] Deutsch Herzzentrum Berlin, Dept Anaesthesiol, D-13354 Berlin, Germany
[2] Deutsch Herzzentrum Berlin, Dept Cardiothorac & Vasc Surg, D-13354 Berlin, Germany
[3] Charite, Dept Lab Med & Pathobiochem, Berlin, Germany
[4] Univ Homburg, Dept Anesthesiol & Intens Care Med, D-6650 Homburg, Germany
关键词
heparin-induced thrombocytopenia type II; anticoagulation; surgery;
D O I
暂无
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Objective:To assess the reliability of the TAS/ecarin clotting time (ECT) for on-line monitoring of r-hirudin in cardiovascular surgery with and without cardiopulmonary bypass (CPB). Design: Samples were spiked with r-hirudin (0 to 5 mu g/mL) and calibration curves constructed. Reproducibility was evaluated by measurement of the sample five times at each concentration. The influence of variations in hematocrit, plasma factors, and platelet count on the test results was examined. Samples were obtained from patients during cardiovascular surgery with CPB (n = 8), without CPB (n = 3), and from volunteers (n = 5) and compared with the laboratory reference tests. All tests were performed in duplicate. Setting: Deutsches Herzzentrum Berlin. Participants:Five healthy volunteers and 11 patients undergoing cardiovascular surgery. Interventions: None. Measurements and Main Results: The TAS/ECT showed linearity and reliability to an r-hirudin concentration of 5 mu g/mL and was not influenced (p < 0.005) by the varying conditions of the in vitro setup. The correlation to the laboratory method was 0.74 for the CPB group and 0.87 for the non-CPB group. Conclusions: The TAS/ECT is a reliable assay for monitoring r-hirudin at the point of care. With this information, the use of r-hirudin during surgery or angioplasty should become more effective and safer. Copyright (C) 2000 by W.B. Saunders Company.
引用
收藏
页码:249 / 252
页数:4
相关论文
共 18 条
[1]   RECOMBINANT HIRUDIN (HBW-023) - BIOLOGICAL DATA OF 10 PATIENTS WITH SEVERE VENOUS THROMBOEMBOLISM [J].
BRIDEY, F ;
DREYFUS, M ;
PARENT, F ;
BROS, A ;
FISCHER, AM ;
CAMEZ, A ;
SIMONNEAU, G ;
DUROUX, P ;
MEYER, D .
AMERICAN JOURNAL OF HEMATOLOGY, 1995, 49 (01) :67-72
[2]   Novel anticoagulants based an direct inhibition of thrombin and factor Xa [J].
Gardell, SJ ;
Sanderson, PEJ .
CORONARY ARTERY DISEASE, 1998, 9 (2-3) :75-81
[3]   Recombinant hirudin (Lepirndin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia -: A prospective study [J].
Greinacher, A ;
Völpel, H ;
Janssens, U ;
Hach-Wunderle, V ;
Kemkes-Matthes, B ;
Eichler, P ;
Mueller-Velten, HG ;
Pötzsch, B .
CIRCULATION, 1999, 99 (01) :73-80
[4]   Anticoagulation in patients with heparin-induced thrombocytopenia type II [J].
Harenberg, J ;
Huhle, G ;
Piazolo, L ;
Wang, LCU ;
Heene, DL .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1997, 23 (02) :189-196
[5]  
Koster A, 1999, BRIT J ANAESTH, V82, P35
[6]   Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin [J].
Koster, A ;
Kuppe, H ;
Hetzer, R ;
Sodian, R ;
Crystal, GJ ;
Mertzlufft, F .
ANESTHESIOLOGY, 1998, 89 (03) :777-780
[7]  
Koster A, 1998, ANESTH ANALG, V86
[8]  
Laposata M, 1998, ARCH PATHOL LAB MED, V122, P799
[9]   Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: Results from the GUSTO-IIb trial [J].
Metz, BK ;
White, HD ;
Granger, CB ;
Simes, RJ ;
Armstrong, PW ;
Hirsh, J ;
Fuster, V ;
MacAulay, CM ;
Califf, RM ;
Topol, EJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (07) :1493-1498
[10]  
MONREAL M, 1994, HAEMOSTASIS, V24, P338